Zurcher Kantonalbank (Zurich Cantonalbank) Rubius Therapeutics, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$30.1 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.79 - $5.98 $2,665 - $20,176	-3,374 Closed	0 $0
Q1 2022 Apr 21, 2022	SELL	$4.25 - $10.4 $27,884 - $68,234	-6,561 Reduced 66.04%	3,374 $19,000
Q4 2021 Feb 01, 2022	SELL	$9.68 - $17.74 $6,369 - $11,672	-658 Reduced 6.21%	9,935 $96,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $985 - $1,450	56 Added 0.53%	10,593 $189,000
Q2 2021 Jul 30, 2021	BUY	$22.26 - $28.43 $79,134 - $101,068	3,555 Added 50.92%	10,537 $257,000
Q1 2021 May 03, 2021	BUY	$8.02 - $32.01 $55,995 - $223,493	6,982 New	6,982 $185,000

Others Institutions Holding RUBY

# of Institutions

Shares Held

325

Call Options Held

Put Options Held

American Portfolios Advisors Holbrook, NY

325
Shares

$0
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Rubius Therapeutics, Inc.

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

More about RUBY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account